<DOC>
	<DOCNO>NCT00818701</DOCNO>
	<brief_summary>The purpose study show low dose recombinant BNP couple phosphodiesterase V inhibition improve renal dysfunction promote relief volume overload patinets acute decompensated heart failure complicate cardiorenal syndrome .</brief_summary>
	<brief_title>Study Low Dose Nesiritide With Without Sildenafil Congestive Heart Failure Patients With Renal Dysfunction</brief_title>
	<detailed_description>Renal dysfunction common comorbidity , well common progressive complication , heart failure ( HF ) . Increasingly , clinical syndrome HF one `` cardiorenal '' failure owe frequent presentation combine cardiac renal dysfunction . Recent study establish prognostic importance renal dysfunction patient chronic HF . An analysis patient second prospective randomize study Ibopamine mortality efficacy ( PRIME ) Hillege et al1 demonstrate estimate glomerular filtration rate ( GFR ) powerful predictor mortality , exceed functional status ejection fraction ( EF ) . In ongoing prospective study , assess neurohumoral renal hemodynamic profile hospitalize patient ADHF develop CRS . Our preliminary finding suggest indeed combination pronounce activation renin-angiotensin-aldosterone system ( RAAS ) , decrease renal perfusion pressure importantly , relative deficiency natriuretic peptide ( despite mark volume overload ) predispose development CRS .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Left ventricular ejection fraction 35 % assessed echocardiography , nuclear scan leave ventriculogram within past 2 year Stable ( NYHA ) class II III symptom define : 1. change NYHA symptom past 3 month ; 2. stable dos ACE inhibitor beta blocker one month ; 3. episode decompensated CHF past 3 month . Calculated creatinine clearance equal le 60 ml/min great 30 ml/min , use CockcroftGault formula assess within past 12 month Nitrates alpha blocker Prior diagnosis intrinsic renal disease include renal artery stenosis &gt; 50 % Peritoneal hemodialysis within 90 day anticipation dialysis ultrafiltration form require study period Hospitalization decompensated CHF past 3 month Myocardial infarction within 3 month screen Unstable angina within 3 month screen evidence myocardial ischemia Significant valvular stenosis , hypertrophic , restrictive obstructive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , biopsy proven active myocarditis Severe congenital heart disease Sustained ventricular tachycardia ventricular fibrillation within 14 day screen Second third degree heart block without permanent cardiac pacemaker Stroke within 3 month screen evidence significantly compromise CNS perfusion Serum sodium &lt; 125 mEq/dL &gt; 150 mEq/dL Serum potassium &lt; 3.5 mEq/dL &gt; 5.7 mEq/dL Hemoglobin &lt; 10 gm/dl Other acute chronic medical condition laboratory abnormality may increase risk associate study participation may interfere interpretation data Received investigational drug within 1 month prior dose Patients allergy iodine . Female subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Congestive Heart Failure NYHF Class 2-3</keyword>
	<keyword>Ejection Fraction 35 less</keyword>
</DOC>